Tomáš Šálek
Advanced hepatocellular carcinoma (HCC) has a dismal prognosis. The multi targeted tyrosine-kinase receptor inhibitor
(TKI) sorafenib is the only proven active substance in systemic HCC therapy for first-line treatment. Since second-line
treatment options have been improved with the successful completion of the RESORCE trial, which demonstrated
a survival benefit for second-line treatment with the TKI regorafenib. Regorafenib is the only systemic treatment shown
to provide a survival benefit in HCC patients progressing on sorafenib treatment. Future trials should explore combinations
of regorafenib with other systemic agents and third-line treatments for patients who fail or who do not tolerate
the sequence of sorafenib and regorafenib.